Olema Pharmaceuticals Changes Name to Olema Oncology
Olema Pharmaceuticals ( ($OLMA) ) just unveiled an update. On November 12, 2026, the company changed its corporate name from Olema Pharmaceuticals, Inc. to Olema Oncology, Inc., after filing an
Compare Stocks
Compare up to 40 stocks
Compared Stocks: 1 / 40
Comparison Results
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 OLMA | Healthcare | $7.56 | 1.70M | $658.80M | -3.20 | ― | Strong Buy |
Top 10 Popular Investment Themes
- Quantum Computing Stocks
- Dividend Stocks
- Magnificent 7 Stocks
- Nuclear Stocks
- Oil Stocks
- Tech Stocks
- Blue Chip Stocks
- Energy Stocks
- Bank Stocks
- Gold Stocks
Popular Stock Pairs
- AAPL vs. MSFT (Apple vs. Microsoft)
- AAPL vs. NVDA (Apple vs. Nvidia)
- AMD vs. INTC (AMD vs. Intel)
- AMZN vs. GOOGL
- AMZN vs. WMT (Amazon vs. Walmart)
- AVGO vs. QCOM (Broadcom vs. Qualcomm)
- COST vs. WMT (Costco vs. Walmart)
- F vs. GM (Ford vs. General Motors)
- GOOGL vs. META (Alphabet vs. Meta)
- HD vs. LOW (Home Depot vs. Lowe's)
- JPM vs. BAC (JPMorgan vs. Bank of America)
- KO vs. PEP (Coca-Cola vs. PepsiCo
- MSFT vs. GOOGL vs. AMZN (Cloud Wars)
- NVDA vs. AMD vs. INTC (Chip Giants)
- NVDA vs. TSM (Nvidia vs. Taiwan Semi)
Performance Comparison
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| OLMA | Olema Pharmaceuticals | 7.56 | -0.84 | -10.00% |
| Name | Price | % Change | |
|---|---|---|---|
| OLMA | $7.56 | -10.00% |
Custom Stock Latest News
Olema Oncology price target lowered to $13 from $18 at Goldman SachsGoldman Sachs lowered the firm’s price target on Olema Oncology (OLMA) to $13 from $18 and keeps a Buy rating on the shares following the Q3 results. Goldman sees a
3d agoOLMA
Olema Oncology reports Q3 EPS (73c), consensus (63c)“As we approach top-line data from our pivotal Phase 3 OPERA-01 trial in the first quarter of 2027, we remain confident in palazestrant’s potential to emerge as a differentiated endocrine
4d agoOLMA
OLMA Earnings Report this Week: Is It a Buy, Ahead of Earnings?Olema Pharmaceuticals, Inc. (OLMA) is scheduled to report 3rd quarter earnings on 11/10/2026. Regarding Q3 estimates, Wall Street analysts expect Olema Pharmaceuticals, Inc. to post earnings of -$0.64 per share.
6d agoOLMA
Olema Pharmaceuticals Updates Board Committees Following ResignationOlema Pharmaceuticals ( ($OLMA) ) has shared an update. On October 12, 2026, Olema Pharmaceuticals, Inc. announced that Dr. Gorjan Hrustanovic had resigned from its Board of Directors, effective October
- Olema Reaffirmed at Buy as Palazestrant Data and SERD Market Momentum Support Unchanged $36 Price Target
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Olema Pharmaceuticals, with a price target of $36.00. Emily Bodnar has given his Buy rating
1M agoOLMA 
Olema Oncology price target lowered to $30 from $48 at StifelStifel lowered the firm’s price target on Olema Oncology (OLMA) to $30 from $48 and keeps a Buy rating on the shares after AstraZeneca (AZN) announced on Friday that its
Olema selloff on Astra miss ‘significant overreaction,’ says JPMorganJPMorgan analyst Anupam Rama keeps an Overweight rating on Olema Oncology (OLMA) after AstraZeneca (AZN) announced that the SERENA-4 study in patients with ER+/HER2- advanced breast cancer missed statistical significance.
Olema Stock Drop Seen as Overdone; OPERA-01 Readout Viewed as Key Upside Catalyst Supporting Buy RatingJ.P. Morgan analyst Anupam Rama has maintained their bullish stance on OLMA stock, giving a Buy rating yesterday. Anupam Rama has given his Buy rating due to a combination of
2M agoOLMA- Olema selloff on AstraZeneca miss a buying opportunity, says Citi
Citi views the pullback in Olema Oncology (OLMA) after AstraZeneca (AZN) announced the camizestrant plus palbociclib combination did not meet the primary endpoint as a buying opportunity. Astra’s SERENA-4 studt
Recent Analysts Ratings of Custom Stocks
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| OLMA | buy | Reiterated | Nov 10, 2026 | |||
| OLMA | buy | Assigned | Nov 10, 2026 | |||
| OLMA | buy | Reiterated | Sep 21, 2026 | |||
| OLMA | buy | Reiterated | Sep 19, 2026 | |||
| OLMA | buy | Reiterated | Sep 14, 2026 | |||
| OLMA | buy | Reiterated | Sep 14, 2026 | |||
| OLMA | buy | Reiterated | Aug 20, 2026 | |||
| OLMA | buy | Reiterated | Aug 10, 2026 | |||
| OLMA | buy | Reiterated | Jun 2, 2026 | |||
| OLMA | hold | Initiated | Mar 26, 2026 |
Most Recent Earnings of Custom Stocks
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| OLMA | Mar 23, 2027TBA | $658.80M | $-0.76 | $0.00 | 0.89 | -3.20 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
- Comprehensive Analysis: Compare up to 40 stocks with detailed metrics including price, market cap, P/E ratio, dividend yield, and more.
- Analyst Ratings: View consensus ratings from top Wall Street analysts and their price targets for each stock.
- Performance Tracking: Analyze historical performance with interactive charts showing 3-month, 6-month, 1-year, YTD, 3-year, and 5-year returns.
- Dividend Information: Evaluate dividend yield, payout ratio, and dividend growth for income-focused investors.
- Earnings Data: Compare earnings per share (EPS), revenue growth, and profitability metrics across companies.
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
All Stock Comparison Categories
- AAPL vs. MSFT (Apple vs. Microsoft)
- AMZN vs. GOOGL
- GOOGL vs. META (Alphabet vs. Meta)
- AAPL vs. NVDA (Apple vs. Nvidia)
- AMZN vs. WMT (Amazon vs. Walmart)
- AMD vs. INTC (AMD vs. Intel)
- AVGO vs. QCOM (Broadcom vs. Qualcomm)
- NVDA vs. TSM (Nvidia vs. Taiwan Semi)
- TSLA vs. RIVN (Tesla vs. Rivian)
- F vs. GM (Ford vs. General Motors)
- TSLA vs. LCID (Tesla vs. Lucid)
- V vs. MA (Visa vs. Mastercard)
- JPM vs. BAC (JPMorgan vs. Bank of America)
- PYPL vs. XYZ (PayPal vs. Block)
- HD vs. LOW (Home Depot vs. Lowe's)
- KO vs. PEP (Coca-Cola vs. PepsiCo
- COST vs. WMT (Costco vs. Walmart)
- NVDA vs. AMD vs. INTC (Chip Giants)
- MSFT vs. GOOGL vs. AMZN (Cloud Wars)
- TSLA vs. F vs. GM (Auto Wars)
- V vs. MA vs. AXP (Credit Cards)
- Quantum Computing Stocks
- Dividend Stocks
- Magnificent 7 Stocks
- Nuclear Stocks
- Oil Stocks
- Tech Stocks
- Blue Chip Stocks
- Energy Stocks
- Bank Stocks
- Gold Stocks
- Growth Stocks
- Bitcoin Stocks
- Meme Stocks
- Biotech Stocks
- Chinese Stocks
- Artificial Intelligence Stocks
- Cannabis Stocks
- Healthcare Stocks
- Value Stocks
- Airline Stocks
- Cybersecurity Stocks
- OpenAI Stocks
- Solar Stocks
- ChatGPT Stocks
- FAANG Stocks
- Green Energy Stocks
- Large Cap Stocks
- Utility Stocks
- Chip Stocks
- Blockchain Stocks
- Social Media Stocks
- Cryptocurrency Stocks
- Electric Vehicle Stocks
- Japanese Stocks
- Casino Stocks
- Metaverse Stocks
- Highest PE Ratio Stocks
- Mega Cap Stocks
- Hotel Stocks
- Green Hydrogen Stocks
- 5g Stocks
- Aerospace and Defense Stocks
- Batmmaan Stocks
- WallStreetBets Stocks
- Virtual Reality Stocks
- Cloud & Storage Stocks
- Lowest P/E Ratio Stocks
- Adtech Stocks
- Biotech & Longevity Plays
- Nuclear Energy Revival Stock
- Onshoring & Rare Earths Supply Stocks
- Popular BDC Stocks
- Private Credit & Fintech Risers
- Quantum Computing Innovators Stocks
- Robotics & Autonomous Systems Stocks
- Beer & Beverage Stocks
- International Value Diversifiers Stocks
- AI Data Center Pivot Miners
- AI Data Center Power Stocks
- Big Oil SAF Refiners (Biofuels)
- Data Center & AI Infrastructure Stocks
- MSFT vs. META (Microsoft vs. Meta)
- Popular South Korean Stocks
- Situational Awareness Q1 Pivot
- Situational Awareness Solar & Battery Bets
- Situational Awareness Top 10 Holdings
- Sustainable Aviation Fuel (SAF) Pure-Plays
- Top Robotics Stocks (Medical, AI & Industrial)
- Top Silver Stocks
- Trump Tariff Risk Stocks (Retail & Tech)
- Trump Tariff Winners (Steel, Manufacturing & Auto)
- Venezuela Oil Recovery (Energy & Services)
- Venezuela Seized Assets (Consumer/Industrial)
Custom Stock - FAQ
Which Custom stocks have a "Strong Buy" analyst rating?
These Custom stocks currently have a "Strong Buy" analyst rating consensus: Olema Pharmaceuticals - Strong Buy, based on 8 analyst ratings, 8 Buy, 0 Hold, and 0 Sell.
Are Custom stocks overpriced?
Olema Pharmaceuticals's stock price is currently $7.56, and its average 12-month price target is N/A.
Which Custom stocks pay dividends?
Olema Pharmaceuticals does not currently pay dividends.